Proteasomal system is involved in the regulation of many cancer related pathways. Targeting proteasome in cancer cells increases the efficiency of cancer therapy. Bortezomib is a first-in-class proteasome inhibitor with FDA approval. Peripheral neuropathy is a dose-limiting toxic side effect of bortezomib. The second-generation proteasome inhibitor carfilzomib is less neurotoxic.